Breaking News

Trilantic Capital Partners Europe Completes Acquisition

Buys 90% stake in leading Italian pharmaceuticals producer Doppel Farmaceutici

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Trilantic Capital Partners Europe, a private equity firm focused on mid-market transactions in Europe, has completed the acquisition of a 90% shareholding in Doppel Farmaceutici after obtaining anti-trust approvals. Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a contract development and manufacturing organization (CDMO).  The investment in Doppel by Trilan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters